Washington, DC – Cooley has advised Blue Owl Capital on a term loan facility of up to $262.5 million for ITM Isotope Technologies Munich SE. The company is known for its work in radiopharmaceutical therapeutics and diagnostics aimed at treating difficult tumors.
The Cooley team advising Blue Owl was led by partners Michael Tollini and Addison Pierce. The team also included Jonathan Cousin, Geoffrey Spolyar, Xander Lee, and Phil Mitchell, who contributed expertise in patent counseling, life sciences, tax, and healthcare regulation.
Cooley has previously assisted Blue Owl with several significant financial transactions. These include a $250 million debt financing with TG Therapeutics in August 2024, an investment of up to $1.05 billion in BridgeBio Pharma in January 2024, and a $140 million investment in XOMA Corporation in December 2023.
Cooley LLP is known for handling transformative deals and complex regulatory matters. It operates across 19 offices worldwide with nearly 1,400 lawyers as part of its workforce exceeding 3,000 people.
The content provided by Cooley is intended for general informational purposes only and does not establish an attorney-client relationship. It is advised that readers seek legal counsel from qualified attorneys within their jurisdiction before acting on any information provided. This content may change without notice and does not guarantee completeness or correctness.
